H1N1ワクチン市場レポート：ワクチンタイプ別、市場タイプ別、地域別、2025年～2033年

H1N1ワクチン市場の世界市場規模は2024年に39億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに56億米ドルに達し、2025～2033年の成長率（CAGR）は4.03%になると予測しています。ヘルスケアへの関心の高まり、医療の大幅な進歩、医療制度の改善、H1N1ワクチンの重要性に対する意識の高まりなどが、市場を後押しする主な要因となっています。

H1N1ワクチンは、インフルエンザA（H1N1）ワクチンとしても知られ、インフルエンザウイルスのH1N1株に対する防御を提供するように設計されています。この株は一般に「豚インフルエンザ」と呼ばれ、2009年に世界的大流行を引き起こしました。H1N1ワクチンには、不活化または弱毒化されたウイルスまたはその成分が含まれており、免疫系がH1N1株に対する抗体を産生するよう促します。これらのワクチンは、感染を予防し、ウイルスの蔓延を緩和するのに役立ちます。これらのワクチンは通常、季節性インフルエンザワクチンの製剤に含まれており、H1N1株とその他の流行中のインフルエンザ株に対する免疫を提供します。

インフルエンザのパンデミック（世界的大流行）の脅威は、H1N1ウイルスの蔓延を防ぐ効果的なワクチンの重要性を浮き彫りにしており、これが世界中でH1N1ワクチン市場の成長を促進する重要な要因の一つとなっています。高いトランスミッション率と重症化の可能性が、公衆衛生を守るためのワクチン需要を促進しています。ワクチン接種の利点に関する意識の高まりや、予防接種プログラムを推進する政府の取り組みが、ワクチン採用を促進し、さらに市場成長に寄与しています。公衆衛生キャンペーンや教育活動も、ワクチン接種率の向上に寄与しています。さらに、世界の人口の相互接続が予防対策の必要性を高めています。国際的な旅行や貿易は感染症の急速な拡大を促進するため、強固なワクチン接種戦略が必要となります。さらに、製薬会社、研究機関、医療機関の協力体制がイノベーションを促進し、タイムリーなワクチン開発を可能にしています。規制当局の支援と合理化された承認プロセスは、ワクチン研究・生産への投資を促進し、世界全体の市場に明るい見通しをもたらしています。

H1N1ワクチン市場傾向/促進要因：

パンデミックへの備えの高まり

将来のパンデミック（世界的大流行）の脅威の高まりは、政府、ヘルスケア機関、個人を予防策としてワクチン接種を優先させる原動力となっており、これが市場の成長を促進しています。疾病のトランスミッションを最小化し、社会的弱者を保護する必要性の高まりが、新型インフルエンザワクチンの需要に拍車をかけています。これに加え、ヘルスケアインフラの改善や各国政府による医療予算の増加が市場成長に寄与しています。

公衆衛生への取り組みの高まり

世界各国の政府や保健当局は、ワクチン接種を促進し、新型インフルエンザワクチンの利点に関する認識を高めるため、公衆衛生キャンペーンをますます打ち出しており、これが市場成長に影響を与えています。このようなイニシアチブは、一般市民を教育し、俗説を払拭し、ウイルスから広く身を守るために積極的なワクチン接種を奨励することに重点を置いています。こうしたキャンペーンは、ワクチン摂取率の向上と地域免疫の改善に寄与しています。また、各国政府は公共ヘルスケア施設の改善に力を入れており、遠隔地や社会から疎外された人々でもアクセスできるようにしています。

世界の旅行と接続の増加

国際的な旅行や接続の増加は、新型インフルエンザのような感染症の急速な蔓延を促進し、新型インフルエンザワクチンの需要をさらに押し上げています。世界人口の相互連結は、トランスミッションを抑制するための集団レベルの免疫の重要性を強調しています。H1N1ワクチンは、旅行者を保護し、輸入やその後のトランスミッションのリスクを軽減することで、国境を越えたアウトブレイクの可能性を減らす上で重要な役割を果たしています。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のH1N1ワクチン市場

• 市場概要
• 市場実績
• COVID-19の影響
• 内訳：ワクチンタイプ別
• 内訳：市場タイプ別
• 主要ブランドの分析
• 内訳：地域別
• 市場予測

第6章 市場内訳：ワクチンタイプ別

• 筋肉内
  • 市場動向
  • 市場予測
• 鼻腔内
  • 市場動向
  • 市場予測
• 皮下
  • 市場動向
  • 市場予測

第7章 市場内訳：市場タイプ別

• 公共
  • 市場動向
  • 市場予測
• プライベート
  • 市場動向
  • 市場予測

第8章 市場内訳：地域別

• アジア太平洋地域
• 北米
• 欧州
• 中東・アフリカ
• ラテンアメリカ

第9章 主要ブランドの分析

• Agripal
• Fiuarix
• Influgen
• Influvac
• Nasovac
• Vaxigrip
• その他

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

• 価格指標
• 価格構造
• マージン分析

第14章 業界の発展

• パイプラインと新製品の発売
• 合併・買収および提携

第15章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • AstraZeneca plc
  • CPL Biologicals Pvt. Ltd
  • CSL Limited
  • Zoetis Inc.

List of Figures

• Figure 1: Global: H1N1 Vaccines Market: Major Drivers and Challenges
• Figure 2: Global: H1N1 Vaccines Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: H1N1 Vaccines Market: Breakup by Vaccines Type (in %), 2024
• Figure 4: Global: H1N1 Vaccines Market: Breakup by Type (in %), 2024
• Figure 5: Global: H1N1 Vaccines Market: Breakup by Region (in %), 2024
• Figure 6: Global: H1N1 Vaccines Industry: SWOT Analysis
• Figure 7: Global: H1N1 Vaccines Industry: Value Chain Analysis
• Figure 8: Global: H1N1 Vaccines Industry: Porter's Five Forces Analysis
• Figure 9: Global: H1N1 Vaccines Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 10: Global: H1N1 Vaccines (Intramuscular) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: H1N1 Vaccines (Intramuscular) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: H1N1 Vaccines (Intranasal) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: H1N1 Vaccines (Intranasal) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: H1N1 Vaccines (Intradermal) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: H1N1 Vaccines (Intradermal) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: H1N1 Vaccines (Public) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: H1N1 Vaccines (Public) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: H1N1 Vaccines (Private) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: H1N1 Vaccines (Private) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: North America: H1N1 Vaccines Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: North America: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Europe: H1N1 Vaccines Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Europe: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Asia Pacific: H1N1 Vaccines Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Asia Pacific: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Middle East and Africa: H1N1 Vaccines Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Middle East and Africa: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Latin America: H1N1 Vaccines Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Latin America: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

• Table 1: Global: H1N1 Vaccines Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: H1N1 Vaccines Market Forecast: Breakup by Vaccines Type (in Million USD), 2025-2033
• Table 3: Global: H1N1 Vaccines Market Forecast: Breakup by Type (in Million USD), 2025-2033
• Table 4: Global: H1N1 Vaccines Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 5: Global: H1N1 Vaccines Market Structure
• Table 6: Global: H1N1 Vaccines Market: Key Players

The global H1N1 vaccines market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.03% during 2025-2033. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.

H1N1 vaccines, also known as influenza A (H1N1) vaccines, are designed to provide protection against the H1N1 strain of the influenza virus. This strain, commonly referred to as ""swine flu,"" caused a global pandemic in 2009. H1N1 vaccines contain inactivated or weakened forms of the virus or its components, prompting the immune system to produce antibodies against the H1N1 strain. These vaccines help prevent infection and mitigate the spread of the virus. They are typically included in seasonal flu vaccine formulations to offer immunity against H1N1 along with other prevalent influenza strains.

The ongoing threat of influenza pandemics underscores the importance of effective vaccines to prevent the spread of the H1N1 virus which represents one of the key factors driving the growth of the H1N1 vaccines market across the globe. High transmission rates and the potential for severe illness drive the demand for vaccines to safeguard public health. The increasing awareness about vaccination benefits and government initiatives to promote immunization programs amplify vaccine adoption which is further contributing to the market growth. Public health campaigns and educational efforts also contribute to higher vaccination rates. Additionally, the global interconnectedness of populations intensifies the need for preventive measures. International travel and trade facilitate the rapid spread of infectious diseases, necessitating robust vaccination strategies. Furthermore, collaborations between pharmaceutical companies, research institutions, and health organizations drive innovation and ensure timely vaccine development. Regulatory support and streamlined approval processes encourage investment in vaccine research and production which is creating a positive outlook for the market across the globe.

H1N1 Vaccines Market Trends/Drivers:

Rise in pandemic preparedness

The rising threat of future pandemics drives governments, healthcare organizations, and individuals to prioritize vaccination as a preventive measure, which is driving the growth of the market. The increasing need to minimize disease transmission and protect vulnerable populations is fueling the demand for H1N1 vaccines. This, along with improving healthcare infrastructure and increasing healthcare budgets by governments of various nations is contributing to the market growth.

Rising public health initiatives

Governments and health authorities worldwide are increasingly launching public health campaigns to promote vaccination and raise awareness about the benefits of H1N1 vaccines which is influencing the market growth. These initiatives focus on educating the public, dispelling myths, and encouraging proactive vaccination to ensure widespread protection against the virus. These campaigns contribute to higher vaccine uptake rates and improved community immunity. Governments of various nations are also focused on improving public healthcare facilities, making them accessible to even the remotest regions and to the marginalized sections, which is facilitating the uptake of the vaccines.

Rise in global travel and connectivity

Increased international travel and connectivity facilitate the rapid spread of infectious diseases like H1N1 which is further propelling the demand for H1N1 vaccines. The interconnectedness of global populations emphasizes the importance of population-level immunity to curb transmission. H1N1 vaccines play a vital role in reducing the potential for cross-border outbreaks by offering protection to travelers and reducing the risk of importation and subsequent transmission.

H1N1 Vaccines Industry Segmentation:

Breakup by Vaccine Type:

• Intramuscular
• Intranasal
• Intradermal

Intramuscular vaccines hold a proven track record of eliciting strong and durable immune responses. The muscle tissue provides an optimal environment for antigen presentation, which leads to effective immune activation and antibody production. This enhances the vaccine's ability to confer protection against H1N1 and other influenza strains. Intramuscular injections are a well-established and familiar method in healthcare settings. Healthcare professionals are experienced in administering vaccines via this route, ensuring accurate dosing and proper delivery. The IM route is suitable for a wide range of age groups, from children to adults. This universality makes IM-administered H1N1 vaccines versatile and applicable in mass vaccination campaigns. Intramuscular injections are commonly associated with vaccination, contributing to public acceptance. People are accustomed to receiving vaccines in this manner, leading to fewer barriers and higher compliance rates.

Breakup by Market Type:

• Public
• Private

H1N1 vaccines serve crucial roles in public health by providing protection against the H1N1 strain of influenza virus. They help prevent widespread outbreaks by building population immunity, reducing the virus's transmission potential. This safeguards vulnerable individuals, such as the elderly, young children, and those with compromised immune systems. H1N1 vaccines minimize illness severity and related complications, reducing hospitalizations, medical costs, and the burden on healthcare systems. By preventing severe cases, vaccines contribute to overall public health and well-being. The widespread H1N1 vaccination efforts contribute to community immunity or herd immunity, indirectly protecting those who cannot be vaccinated due to medical reasons. This collaborative defense limits the virus's spread within the population. Furthermore, H1N1 vaccines play a pivotal role in pandemic preparedness, as they form the foundation for rapid response to emerging influenza strains with pandemic potential.

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

In North America, the H1N1 vaccines market is driven by factors, including proactive public health initiatives, well-established vaccination programs, and a strong healthcare infrastructure. The memory of past outbreaks and pandemics, such as the 2009 H1N1 pandemic, has heightened awareness about the importance of vaccination. Robust healthcare systems, accessible medical facilities, and high levels of health literacy contribute to a culture of vaccination. Additionally, government support, regulatory frameworks, and public-private partnerships facilitate timely vaccine development, distribution, and administration. These factors collectively promote the demand for H1N1 vaccines, ensuring preparedness and protection against influenza outbreaks in North America.

Competitive Landscape:

Key players in the H1N1 vaccines market are actively engaged in several strategic initiatives to address the demand for effective vaccines and ensure public health preparedness. These companies focus on continuous research and development (R&D) to create vaccines with enhanced immunogenicity and broader coverage against H1N1 and related strains. Collaborations with research institutions and health authorities enable them to stay informed about evolving virus strains and pandemic potential. Moreover, key players invest in production scalability and efficiency to meet demand during outbreaks. They work closely with regulatory agencies to ensure vaccine safety, efficacy, and timely approvals. In addition, these companies engage in public health advocacy, promoting vaccination through education and awareness campaigns. Furthermore, collaborations with global health organizations, governments, and non-profit entities ensure equitable vaccine distribution, especially in regions with limited access to healthcare. By prioritizing innovation, safety, and accessibility, key players contribute to effective disease prevention and control in the H1N1 vaccines market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• AstraZeneca plc
• CPL Biologicals Pvt. Ltd
• CSL Limited
• Zoetis Inc.

Key Questions Answered in This Report

• 1.What was the size of the global H1N1 vaccines market in 2024?
• 2.What is the expected growth rate of the global H1N1 vaccines market during 2025-2033?
• 3.What are the key factors driving the global H1N1 vaccines market?
• 4.What has been the impact of COVID-19 on the global H1N1 vaccines market?
• 5.What is the breakup of the global H1N1 vaccines market based on the vaccine type?
• 6.What is the breakup of the global H1N1 vaccines market based on the market type?
• 7.What are the key regions in the global H1N1 vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global H1N1 Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Breakup by Vaccines Type
• 5.5 Breakup by Market Type
• 5.6 Analysis of Key Brands
• 5.7 Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Vaccines Type

• 6.1 Intramuscular
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Intranasal
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Intradermal
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Type

• 7.1 Public
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Private
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Analysis of Key Brand

• 9.1 Agripal
• 9.2 Fiuarix
• 9.3 Influgen
• 9.4 Influvac
• 9.5 Nasovac
• 9.6 Vaxigrip
• 9.7 Others

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

• 13.1 Price Indicators
• 13.2 Price Structure
• 13.3 Margin Analysis

14 Industry Developments

• 14.1 Pipeline and New Product Launches
• 14.2 Mergers & Acquisitions and Partnerships

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 AstraZeneca plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 CPL Biologicals Pvt. Ltd
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 CSL Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Zoetis Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis